B Meiser
Overview
Explore the profile of B Meiser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
1298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gleeson M, Kentwell M, Meiser B, Do J, Nevin S, Taylor N, et al.
Gynecol Oncol
. 2020 May;
158(2):431-439.
PMID: 32451123
Background: BRCA1/2 mutation status has increasing relevance for ovarian cancer treatments, making traditional coordination of genetic testing by genetic services unsustainable. Consequently alternative models of genetic testing have been developed...
2.
Yanes T, Kaur R, Meiser B, Scheepers-Joynt M, McInerny S, Barlow-Stewart K, et al.
Fam Cancer
. 2020 May;
19(4):297-306.
PMID: 32430685
It is estimated that polygenic factors can explain up to 18% of familial breast cancer. Clinical implementation of polygenic testing has begun, with several commercial laboratories now testing. Despite commercial...
3.
Meiser B, Kaur R, Kirk J, Morrow A, Peate M, Wong W, et al.
Fam Cancer
. 2020 May;
19(4):337-346.
PMID: 32385704
Introduction: This nationwide study assessed the impact of Lynch syndrome-related risk management guidelines on clinicians' recommendations of risk management strategies to carriers of pathogenic variants in mismatch repair genes and...
4.
ONeill R, Meiser B, Emmanuel S, Williams D, Stoita A
Fam Cancer
. 2019 Oct;
19(1):23-35.
PMID: 31625003
Screening for pancreatic cancer (PC) in high-risk groups aimed to detect early cancers is currently done only in the research setting, and data on psychological outcomes of screening in these...
5.
Meiser B, Wong W, Peate M, Julian-Reynier C, Kirk J, Mitchell G
Hered Cancer Clin Pract
. 2017 Sep;
15:14.
PMID: 28943990
Background: Selective estrogen receptor modulators, such as tamoxifen, reduce breast cancer risk by up to 50% in women at increased risk for breast cancer. Despite tamoxifen's well-established efficacy, many studies...
6.
Watts K, Meiser B, Zilliacus E, Kaur R, Taouk M, Girgis A, et al.
Eur J Cancer Care (Engl)
. 2017 Sep;
27(2):e12758.
PMID: 28892208
This study aimed to ascertain the systemic barriers encountered by oncology health professionals (HPs) working with patients from ethnic minorities to guide the development of a communication skills training programme....
7.
Liang R, Meiser B, Smith S, Kasparian N, Lewis C, Chin M, et al.
Eur J Cancer Care (Engl)
. 2016 Oct;
26(6).
PMID: 27730730
Somatic mutations in key oncogenes in non-small cell lung cancer (NSCLC) and melanoma are important determinants of tumour sensitivity to targeted therapies. Molecular screening for these predictive biomarkers is routinely...
8.
Willis A, Smith S, Meiser B, Ballinger M, Thomas D, Young M
Clin Genet
. 2016 Sep;
92(2):121-133.
PMID: 27643459
Evidence suggests that a significant proportion of individuals referred to cancer genetic counselling (GC) do not attend, and thus may not be engaged in adequate cancer risk management. We aimed...
9.
Meiser B, Quinn V, Gleeson M, Kirk J, Tucker K, Rahman B, et al.
Eur J Hum Genet
. 2016 Jun;
24(11):1517-1523.
PMID: 27329735
Selection of women for treatment-focused genetic testing (TFGT) following a new diagnosis of breast cancer is changing. Increasingly a patient's age and tumour characteristics rather than only their family history...
10.
Willis A, Smith S, Meiser B, Muller C, Lewis S, Halliday J
Prenat Diagn
. 2014 Sep;
35(1):100-2.
PMID: 25196282
No abstract available.